World News

Isomorphic Labs plans to use the new capital to further develop and deploy its proprietary AI drug design engine, known as IsoDDE.

The acquisition will give Zydus access to Assertio’s commercial infrastructure in the US specialty pharmaceutical market, particularly in oncology supportive care and pain management therapies.

The approval applies to adolescents and adults weighing at least 35 kilograms who have haemophilia A with factor VIII inhibitors or haemophilia B with factor IX inhibitors.

NICE recommended Imfinzi for adults whose stomach cancer has not spread extensively and can be removed through surgery, including gastric and gastro-oesophageal junction cancers that physicians frequently diagnose at advanced stages.

The acquisition includes MacroGenics’ biologics drug substance manufacturing facility in Rockville, Maryland, as well as a warehousing center in Frederick, Maryland, located about 30 miles away.

In addition, the investment will strengthen research into emerging treatment areas such as heart failure and renal denervation, a minimally invasive therapy for uncontrolled hypertension.

The acquisition follows Stryker’s earlier move into the vascular intervention market through its approximately US$4.9 billion purchase of Inari Medical in 2025.

CTTQ will also purchase a supply of bepirovirsen for an initial period of five and a half years, while GSK will record product sales from the arrangement, though the companies are not disclosing the financial value of the deal.

The new 250,000-square-foot (23,226-square-metre) Bellwether Laboratory will significantly expand global production capacity for actinium-225 (Ac-225).

The new CFO succeeds Henrik Bøggild, who left the company after three and a half years to pursue another professional opportunity.